Search Within

Daniel C Danila

  1. "Molecular Imaging and Therapy Service"
Formats
  1. Journal Article (16)
  2. Meeting Abstract (15)
Groups
  1. Department of Medicine (31)
  2. Genitourinary Oncology Service (31)
  3. Molecular Imaging and Therapy Service (31)
  4. Solid Tumor Oncology Division (31)
  5. Radiology, Department of (26)
  6. GSK Faculty (25)

More Groups

People
  1. Howard Scher (26)
  2. Michael Morris (25)
  3. Steven Larson (20)
  4. Martin Fleisher (13)
  5. Susan Slovin (13)
  6. Dana Rathkopf (12)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2022 (1)
  4. 2021 (3)
  5. 2020 (1)
  6. 2019 (3)

More Years

Publications
  1. Journal of Clinical Oncology (12)
  2. Clinical Cancer Research (3)
  3. Journal of Nuclear Medicine (3)
  4. Cancer Research (2)
  5. JAMA Oncology (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. American Association for Cancer Research (6)
  3. Society of Nuclear Medicine (3)
  4. American Medical Association (2)
  5. Elsevier Inc. (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (31)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making
    Journal Article

    Abida, W.; Armenia, J.; Gopalan, A.; Brennan, R.; Walsh, M.; Barron, D.; Danila, D.; Rathkopf, D.; Morris, M.; Slovin, S.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer
    Journal Article

    O'Shaughnessy, M. J.; McBride, S. M.; Vargas, H. A.; Touijer, K. A.; Morris, M. J.; Danila, D. C.; Laudone, V. P.; Bochner, B. H.; Sheinfeld, J.; Dayan, E. S.; more...
    Urology (2017)

    Fulltext@MSK | Save
  • Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H.; Graf, R.; Schreiber, N.; Lu, D.; Louw, J.; Alvarez, H. A. V.; Bambury, R.; Danila, D.; McLaughlin, B.; Heller, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Lu, D.; Schreiber, N. A.; Louw, J.; Graf, R. P.; Vargas, H. A.; Johnson, A.; Jendrisak, A.; Bambury, R.; Danila, D.; more...
    JAMA Oncology (2016)

    Fulltext@MSK | Save
  • A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with (89)Zr-Df-IAB2M in metastatic prostate cancer (PCa)
    Meeting Abstract

    Morris, M. J.; Martinez, D. F.; Durack, J. C.; Slovin, S. F.; Danila, D. C.; O'Donoghue, J. A.; Parada, N. A.; Lyashchenko, S. K.; Carrasquillo, J. A.; Ruan, S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Wholebody clearance of three (89)Zr labeled antibodies: Differences between PET based and whole body probe based clearance
    Meeting Abstract

    Beylergil, V.; Pandit-Taskar, N.; Larson, S.; Morris, M.; Danila, D. C.; Bander, N.; Fine, B.; Carrasquillo, J.; Weber, W.; O'Donoghue, J.
    Journal of Nuclear Medicine (2015)

    Fulltext@MSK | Save
  • STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Danila, D. C.; Fleisher, M.; Carrasquillo, J. A.; Gilbert, H.; Morris, M. J.; Bellomo, L. P.; Hendrikx, P. J.; Szafer-Glusman, E.; Herkal, A.; Patel, C.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Initial PET imaging and pharmacokinetic results from a Phase I/II study of Zr-89-labeled anti-STEAP1 antibody in metastatic castrate-resistant prostate cancer (mCRPC) patients
    Meeting Abstract

    Carrasquillo, J. A.; Danila, D. C.; Beylergil, V.; O'Donoghue, J. A.; Cheal, S. M.; Ruan, S. T.; Pandit-Taskar, N.; Fox, J. J.; Fleming, S. E.; Zanzonico, P. B.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
    Journal Article

    Rathkopf, D. E.; Morris, M. J.; Fox, J. J.; Danila, D. C.; Slovin, S. F.; Hager, J. H.; Rix, P. J.; Chow-Maneval, E.; Chen, I.; Gonen, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save